Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 18/2011

01-12-2011 | Leading Article

Epigenetic-Based Therapies in Cancer

Progress to Date

Authors: Sang-Hyun Song, Sae-Won Han, Professor Yung-Jue Bang, MD, PhD

Published in: Drugs | Issue 18/2011

Login to get access

Abstract

Epigenetic gene silencing is a hallmark of cancer cells. Two important types of epigenetic changes are DNA methylation and histone modification. These modifications are catalysed by DNA methyltransferases (DNMTs) and histone deacetylases (HDACs), resulting in chromatin structure changes and gene inactivation. Interestingly, inhibition of these enzymes is known to induce differentiation or apoptosis of cancer cells. Therefore, DNMTs and HDACs have become attractive therapeutic targets. In recent years, many different DNMT and HDAC inhibitors have been developed, and multiple molecular mechanisms through which these agents exert anti-cancer effects have been identified. While a large number of clinical trials are ongoing, hypomethylating agents and HDAC inhibitors seem to be promising for treating several types of cancer. Moreover, developing effective strategies of combining epigenetic therapy with conventional chemotherapy will be one of the major challenges in the future.
We briefly review current advances in epigenetic therapies with a focus on recently reported clinical trials.
Literature
1.
2.
Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006 Jan; 5(1): 37–50PubMedCrossRef
3.
Jones PA, Liang G. Rethinking how DNA methylation patterns are maintained. Nat Rev Genet 2009 Nov; 10(11): 805–11PubMedCrossRef
4.
Robertson KD, Uzvolgyi E, Liang G, et al. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and over-expression in tumors. Nucleic Acids Res 1999 Jun 1; 27(11): 2291–8PubMedCrossRef
5.
Okano M, Bell DW, Haber DA, et al. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999 Oct 29; 99(3): 247–57PubMedCrossRef
6.
Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 1992 Jun 12; 69(6): 915–26PubMedCrossRef
7.
8.
Wagner JM, Hackanson B, Lubbert M, et al. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics 2010 Dec; 1(3–4): 117–36PubMedCrossRef
9.
Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997 Sep 25; 389(6649): 349–52PubMedCrossRef
10.
Zhu P, Martin E, Mengwasser J, et al. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004 May; 5(5): 455–63PubMedCrossRef
11.
Ropero S, Fraga MF, Ballestar E, et al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet 2006 May; 38(5): 566–9PubMedCrossRef
12.
Ma X, Ezzeldin HH, Diasio RB. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 2009 Oct 1; 69(14): 1911–34PubMedCrossRef
13.
Kristensen LS, Nielsen HM, Hansen LL. Epigenetics and cancer treatment. Eur J Pharmacol 2009 Dec 25; 625(1–3): 131–42PubMedCrossRef
14.
Vigna E, Recchia AG, Madeo A, et al. Epigenetic regulation in myelodysplastic syndromes: implications for therapy. Expert Opin Investig Drugs 2011 Apr; 20(4): 465–93PubMed
15.
Yang X, Lay F, Han H, et al. Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci 2010 Nov; 31(11): 536–46PubMedCrossRef
16.
Mai A, Altucci L. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol 2009 Jan; 41(1): 199–213PubMedCrossRef
17.
Kaminskas E, Farrell AT, Wang YC, et al. FDA drug approval summary: azacitidine (5-azacytidine, vidaza) for injectable suspension. Oncologist 2005 Mar; 10(3): 176–82PubMedCrossRef
18.
Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006 Apr 15; 106(8): 1794–803PubMedCrossRef
19.
Herranz M, Martin-Caballero J, Fraga MF, et al. The novel DNA methylation inhibitor zebularine is effective against the development of murine T-cell lymphoma. Blood 2006 Feb 1; 107(3): 1174–7PubMedCrossRef
20.
Beumer JH, Eiseman JL, Parise RA, et al. Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine in mice. Clin Cancer Res 2006 Dec 15; 12(24): 7483–91PubMedCrossRef
21.
Boothman DA, Briggle TV, Greer S. Tumor-selective metabolism of 5-fluoro-2′-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil in mice bearing Lewis lung carcinoma. Cancer Res 1987 May 1; 47(9): 2354–62PubMed
22.
Siedlecki P, Garcia Boy R, Musch T, et al. Discovery of two novel, small-molecule inhibitors of DNA methylation. J Med Chem 2006 Jan 26; 49(2): 678–83PubMedCrossRef
23.
Goffin J, Eisenhauer E. DNA methyltransferase inhibitors-state of the art. Ann Oncol 2002 Nov; 13(11): 1699–716PubMedCrossRef
24.
Coronel J, Cetina L, Pacheco I, et al. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer: preliminary results. Med Oncol. Epub 2010 Oct 8
25.
Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004 Sep 1; 104(5): 1266–9PubMedCrossRef
26.
Kuendgen A, Knipp S, Fox F, et al. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol 2005 Dec; 84 Suppl. 1: 61–6PubMedCrossRef
27.
Yoshida M, Kijima M, Akita M, et al. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990 Oct 5; 265(28): 17174–9PubMed
28.
Prebet T, Vey N. Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. Expert Opin Investig Drugs 2011 Feb; 20(2): 287–95PubMedCrossRef
29.
Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009 Nov 10; 27(32): 5410–7PubMedCrossRef
30.
Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010 Oct 10; 28(29): 4485–91PubMedCrossRef
31.
Gore L, Rothenberg ML, O’Bryant CL, et al. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res 2008 Jul 15; 14(14): 4517–25PubMedCrossRef
32.
Kantarjian HM, O’Brien S, Shan J, et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 2007 Jan 15; 109(2): 265–73PubMedCrossRef
33.
Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002 May 15; 20(10): 2429–40PubMedCrossRef
34.
Plimack ER, Kantarjian HM, Issa JP. Decitabine and its role in the treatment of hematopoietic malignancies. Leuk Lymphoma 2007 Aug; 48(8): 1472–81PubMedCrossRef
35.
Robak T. New nucleoside analogs for patients with hematological malignancies. Expert Opin Investig Drugs 2011 Mar; 20(3): 343–59PubMedCrossRef
36.
Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 2008 Jul 1; 123(1): 8–13PubMedCrossRef
37.
Beisler JA. Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine. J Med Chem 1978 Feb; 21(2): 204–8PubMedCrossRef
38.
Santi DV, Norment A, Garrett CE. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci U S A 1984 Nov; 81(22): 6993–7PubMedCrossRef
39.
Gowher H, Jeltsch A. Mechanism of inhibition of DNA methyltransferases by cytidine analogs in cancer therapy. Cancer Biol Ther 2004 Nov; 3(11): 1062–8PubMedCrossRef
40.
Kim CH, Marquez VE, Mao DT, et al. Synthesis of pyrimidin-2-one nucleosides as acid-stable inhibitors of cytidine deaminase. J Med Chem 1986 Aug; 29(8): 1374–80PubMedCrossRef
41.
Cheng JC, Matsen CB, Gonzales FA, et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 2003 Mar 5; 95(5): 399–409PubMedCrossRef
42.
Yoo CB, Cheng JC, Jones PA. Zebularine: a new drug for epigenetic therapy. Biochem Soc Trans 2004 Dec; 32 (Pt 6): 910–2PubMedCrossRef
43.
Champion C, Guianvarc’h D, Senamaud-Beaufort C, et al. Mechanistic insights on the inhibition of c5 DNA methyltransferases by zebularine. PLoS One 2010; 5(8): e12388PubMedCrossRef
44.
Cheng JC, Weisenberger DJ, Gonzales FA, et al. Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol 2004 Feb; 24(3): 1270–8PubMedCrossRef
45.
Cheng JC, Yoo CB, Weisenberger DJ, et al. Preferential response of cancer cells to zebularine. Cancer Cell 2004 Aug; 6(2): 151–8PubMedCrossRef
46.
Reinisch KM, Chen L, Verdine GL, et al. The crystal structure of HaeIII methyltransferase convalently complexed to DNA: an extrahelical cytosine and rearranged base pairing. Cell 1995 Jul 14; 82(1): 143–53PubMedCrossRef
47.
48.
Garcia-Manero G. Demethylating agents in myeloid malignancies. Curr Opin Oncol 2008 Nov; 20(6): 705–10PubMedCrossRef
49.
Santos FP, Kantarjian H, Garcia-Manero G, et al. Decitabine in the treatment of myelodysplastic syndromes. Expert Rev Anticancer Ther 2010 Jan; 10(1): 9–22PubMedCrossRef
50.
Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980 May; 20(1): 85–93PubMedCrossRef
51.
Creusot F, Acs G, Christman JK. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine. J Biol Chem 1982 Feb 25; 257(4): 2041–8PubMed
52.
Pinto A, Attadia V, Fusco A, et al. 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 1984 Oct; 64(4): 922–9PubMed
53.
Kornblith AB, Herndon 2nd JE, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 2002 May 15; 20(10): 2441–52PubMedCrossRef
54.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009 Mar; 10(3): 223–32PubMedCrossRef
55.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010 Feb 1; 28(4): 562–9PubMedCrossRef
56.
Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004 Mar 1; 103(5): 1635–40PubMedCrossRef
57.
Issa JP, Gharibyan V, Cortes J, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 2005 Jun 10; 23(17): 3948–56PubMedCrossRef
58.
Kantarjian HM, O’Brien S, Huang X, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 2007 Mar 15; 109(6): 1133–7PubMedCrossRef
59.
Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007 Jan 1; 109(1): 52–7PubMedCrossRef
60.
Daskalakis M, Nguyen TT, Nguyen C, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 2002 Oct 15; 100(8): 2957–64PubMedCrossRef
61.
Blum W, Klisovic RB, Hackanson B, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007 Sep 1; 25(25): 3884–91PubMedCrossRef
62.
Stewart DJ, Issa JP, Kurzrock R, et al. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res 2009 Jun 1; 15(11): 3881–8PubMedCrossRef
63.
Zhou L, Cheng X, Connolly BA, et al. Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol 2002 Aug 23; 321(4): 591–9PubMedCrossRef
64.
Balch C, Yan P, Craft T, et al. Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol Cancer Ther 2005 Oct; 4(10): 1505–14PubMedCrossRef
65.
Holleran JL, Parise RA, Joseph E, et al. Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine. Clin Cancer Res 2005 May 15, 2005; 11(10): 3862–8PubMedCrossRef
66.
67.
Beumer JH, Parise RA, Newman EM, et al. Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU). Cancer Chemother Pharmacol 2008 Jul; 62(2): 363–8PubMedCrossRef
68.
Brueckner B, Lyko F. DNA methyltransferase inhibitors: old and new drugs for an epigenetic cancer therapy. Trends Pharmacol Sci 2004 Nov; 25(11): 551–4PubMedCrossRef
69.
Brueckner B, Garcia Boy R, Siedlecki P, et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res 2005 Jul 15; 65(14): 6305–11PubMedCrossRef
70.
Stresemann C, Brueckner B, Musch T, et al. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res 2006 Mar 1; 66(5): 2794–800PubMedCrossRef
71.
Suzuki T, Tanaka R, Hamada S, et al. Design, synthesis, inhibitory activity, and binding mode study of novel DNA methyltransferase 1 inhibitors. Bioorg Med Chem Lett 2010 Feb 1; 20(3): 1124–7PubMedCrossRef
72.
Plummer R, Vidal L, Griffin M, et al. Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors. Clin Cancer Res 2009 May 1; 15(9): 3177–83PubMedCrossRef
73.
Winquist E, Knox J, Ayoub JP, et al. Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study. Invest New Drugs 2006 Mar; 24(2): 159–67PubMedCrossRef
74.
Song Y, Zhang C. Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression. Cancer Chemother Pharmacol 2009 Mar; 63(4): 605–13PubMedCrossRef
75.
Segura-Pacheco B, Trejo-Becerril C, Perez-Cardenas E, et al. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin Cancer Res 2003 May; 9(5): 1596–603PubMed
76.
Arce C, Segura-Pacheco B, Perez-Cardenas E, et al. Hydralazine target: from blood vessels to the epigenome. J Transl Med 2006 Feb 28; 4: 10PubMedCrossRef
77.
Chavez-Blanco A, Perez-Plasencia C, Perez-Cardenas E, et al. Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int 2006 Jan 31; 6: 2PubMedCrossRef
78.
Candelaria M, Gallardo-Rincon D, Arce C, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol 2007 Sep; 18(9): 1529–38PubMedCrossRef
79.
Newmark HL, Young CW. Butyrate and phenylacetate as differentiating agents: practical problems and opportunities. J Cell Biochem Suppl 1995; 22: 247–53PubMedCrossRef
80.
Kelly WK, O’Connor OA, Marks PA. Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Investig Drugs 2002 Dec; 11(12): 1695–713PubMedCrossRef
81.
Gottlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001 Dec 17; 20(24): 6969–78PubMedCrossRef
82.
Kramer OH, Zhu P, Ostendorff HP, et al. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC 2. EMBO J 2003 Jul 1; 22(13): 3411–20PubMedCrossRef
83.
Milutinovic S, D’Alessio AC, Detich N, et al. Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes. Carcinogenesis 2007 Mar; 28(3): 560–71PubMedCrossRef
84.
Kelly WK, O’Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005 Jun 10; 23(17): 3923–31PubMedCrossRef
85.
Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007 Jan 1; 109(1): 31–9PubMedCrossRef
86.
Ueda H, Nakajima H, Hori Y, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968: I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo) 1994 Mar; 47(3): 301–10
87.
Furumai R, Matsuyama A, Kobashi N, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002 Sep 1; 62(17): 4916–21PubMed
88.
Suzuki T, Ando T, Tsuchiya K, et al. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Med Chem 1999 Jul 29; 42(15): 3001–3PubMedCrossRef
89.
Saito A, Yamashita T, Mariko Y, et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A 1999 Apr 13; 96(8): 4592–7PubMedCrossRef
90.
Huang X, Gao L, Wang S, et al. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression. Cancer Res 2009 Nov 1; 69(21): 8403–11PubMedCrossRef
91.
Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the reexpression of genes silenced in cancer. Nat Genet 1999 Jan; 21(1): 103–7PubMedCrossRef
92.
Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 2006 Nov 15; 108(10): 3271–9PubMedCrossRef
93.
Braiteh F, Soriano AO, Garcia-Manero G, et al. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res 2008 Oct 1; 14(19): 6296–301PubMedCrossRef
94.
Scherpereel A, Berghmans T, Lafitte JJ, et al. Valproatedoxorubicin: promising therapy for progressing mesothelioma: a phase II study. Eur Respir J 2011 Jan; 37(1): 129–35PubMedCrossRef
95.
Yoshimi A, Kurokawa M. Key roles of histone methyl-transferase and demethylase in leukemogenesis. J Cell Biochem 2011 Feb; 112(2): 415–24PubMedCrossRef
96.
Huang Y, Greene E, Murray Stewart T, et al. Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc Natl Acad Sci U S A 2007 May 8; 104(19): 8023–8PubMedCrossRef
Metadata
Title
Epigenetic-Based Therapies in Cancer
Progress to Date
Authors
Sang-Hyun Song
Sae-Won Han
Professor Yung-Jue Bang, MD, PhD
Publication date
01-12-2011
Publisher
Springer International Publishing
Published in
Drugs / Issue 18/2011
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/11596690-000000000-00000

Other articles of this Issue 18/2011

Drugs 18/2011 Go to the issue

Adis Drug Evaluation

Celecoxib

Adis Drug Profile

Fidaxomicin

Adis Drug Profile

Belimumab

Adis Drug Evaluation

Pegylated Liposomal Doxorubicin

Current Opinion

Gastro-Oesophageal Reflux Disease

Erratum

Erratum to: Eldecalcitol: a review of its use in the treatment of osteoporosis